Antimicrobial stewardship is imperative when treating bacterial infections because the misuse and overuse of antibiotics have caused pathogens to develop life-threatening resistance mechanisms. The New Delhi metallo-beta-lactamase (NDM-1) is one of many enzymes that enable bacterial resistance. NDM-1 is a more recently discovered beta-lactamase with the ability to inactivate a wide range of beta-lactam antibiotics. Multiple NDM-1 inhibitors have been designed and tested; however, due to the complexity of the NDM-1 active site, there is currently no inhibitor on the market. Consequently, an infection caused by bacteria possessing the gene for the NDM-1 enzyme is a serious and potentially fatal complication. An abundance of research has been invested over the past decade in search of an NDM-1 inhibitor. This review aims to summarize various NDM-1 inhibitor designs that have been developed in recent years.
Keywords: BL; Concentration inhibiting the 50% of The enzyme; IC(50); Inhibition constant; K(i); MBL; MIC; MRSA; Metallo β-Lactamase; Methicillin-resistant staphylococcus aureus; Minimum inhibition concentration; NDM-1; New Delhi MBL-1; SAR; Structure-activity relationship; β-Lactamase.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.